Switching addictions between HER2 and FGFR2 in HER2-positive breast tumor cells: FGFR2 as a potential target for salvage after lapatinib failure

Koichi Azuma, Junji Tsurutani, Kazuko Sakai, Hiroyasu Kaneda, Yasuhito Fujisaka, Masayuki Takeda, Masahiro Watatani, Tokuzo Arao, Taroh Satoh, Isamu Okamoto, Takayasu Kurata, Kazuto Nishio, Kazuhiko Nakagawa

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Agents that target HER2 have improved the prognosis of patients with HER2-amplified breast cancers. However, patients who initially respond to such targeted therapy eventually develop resistance to the treatment. We have established a line of lapatinib-resistant breast cancer cells (UACC812/LR) by chronic exposure of HER2-amplified and lapatinib-sensitive UACC812 cells to the drug. The mechanism by which UACC812/LR acquired resistance to lapatinib was explored using comprehensive gene hybridization. The FGFR2 gene in UACC812/LR was highly amplified, accompanied by overexpression of FGFR2 and reduced expression of HER2, and a cell proliferation assay showed that the IC50 of PD173074, a small-molecule inhibitor of FGFR tyrosine kinase, was 10,000 times lower in UACC812/LR than in the parent cells. PD173074 decreased the phosphorylation of FGFR2 and substantially induced apoptosis in UACC812/LR, but not in the parent cells. FGFR2 appeared to be a pivotal molecule for the survival of UACC812/LR as they became independent of the HER2 pathway, suggesting that a switch of addiction from the HER2 to the FGFR2 pathway enabled cancer cells to become resistant to HER2-targeted therapy. The present study is the first to implicate FGFR in the development of resistance to lapatinib in cancer, and suggests that FGFR-targeted therapy might become a promising salvage strategy after lapatinib failure in patients with HER2-positive breast cancer.

Original languageEnglish
Pages (from-to)219-224
Number of pages6
JournalBiochemical and Biophysical Research Communications
Volume407
Issue number1
DOIs
Publication statusPublished - Apr 1 2011
Externally publishedYes

Fingerprint

Salvaging
Tumors
Cells
Breast Neoplasms
Genes
Phosphorylation
Molecules
Cell proliferation
Therapeutics
Protein-Tyrosine Kinases
Inhibitory Concentration 50
Assays
Neoplasms
Switches
Cell Proliferation
lapatinib
Apoptosis
Survival
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Biophysics
  • Biochemistry
  • Molecular Biology
  • Cell Biology

Cite this

Switching addictions between HER2 and FGFR2 in HER2-positive breast tumor cells : FGFR2 as a potential target for salvage after lapatinib failure. / Azuma, Koichi; Tsurutani, Junji; Sakai, Kazuko; Kaneda, Hiroyasu; Fujisaka, Yasuhito; Takeda, Masayuki; Watatani, Masahiro; Arao, Tokuzo; Satoh, Taroh; Okamoto, Isamu; Kurata, Takayasu; Nishio, Kazuto; Nakagawa, Kazuhiko.

In: Biochemical and Biophysical Research Communications, Vol. 407, No. 1, 01.04.2011, p. 219-224.

Research output: Contribution to journalArticle

Azuma, K, Tsurutani, J, Sakai, K, Kaneda, H, Fujisaka, Y, Takeda, M, Watatani, M, Arao, T, Satoh, T, Okamoto, I, Kurata, T, Nishio, K & Nakagawa, K 2011, 'Switching addictions between HER2 and FGFR2 in HER2-positive breast tumor cells: FGFR2 as a potential target for salvage after lapatinib failure', Biochemical and Biophysical Research Communications, vol. 407, no. 1, pp. 219-224. https://doi.org/10.1016/j.bbrc.2011.03.002
Azuma, Koichi ; Tsurutani, Junji ; Sakai, Kazuko ; Kaneda, Hiroyasu ; Fujisaka, Yasuhito ; Takeda, Masayuki ; Watatani, Masahiro ; Arao, Tokuzo ; Satoh, Taroh ; Okamoto, Isamu ; Kurata, Takayasu ; Nishio, Kazuto ; Nakagawa, Kazuhiko. / Switching addictions between HER2 and FGFR2 in HER2-positive breast tumor cells : FGFR2 as a potential target for salvage after lapatinib failure. In: Biochemical and Biophysical Research Communications. 2011 ; Vol. 407, No. 1. pp. 219-224.
@article{4bfb5cbbd3c84fc18f0544609091dce1,
title = "Switching addictions between HER2 and FGFR2 in HER2-positive breast tumor cells: FGFR2 as a potential target for salvage after lapatinib failure",
abstract = "Agents that target HER2 have improved the prognosis of patients with HER2-amplified breast cancers. However, patients who initially respond to such targeted therapy eventually develop resistance to the treatment. We have established a line of lapatinib-resistant breast cancer cells (UACC812/LR) by chronic exposure of HER2-amplified and lapatinib-sensitive UACC812 cells to the drug. The mechanism by which UACC812/LR acquired resistance to lapatinib was explored using comprehensive gene hybridization. The FGFR2 gene in UACC812/LR was highly amplified, accompanied by overexpression of FGFR2 and reduced expression of HER2, and a cell proliferation assay showed that the IC50 of PD173074, a small-molecule inhibitor of FGFR tyrosine kinase, was 10,000 times lower in UACC812/LR than in the parent cells. PD173074 decreased the phosphorylation of FGFR2 and substantially induced apoptosis in UACC812/LR, but not in the parent cells. FGFR2 appeared to be a pivotal molecule for the survival of UACC812/LR as they became independent of the HER2 pathway, suggesting that a switch of addiction from the HER2 to the FGFR2 pathway enabled cancer cells to become resistant to HER2-targeted therapy. The present study is the first to implicate FGFR in the development of resistance to lapatinib in cancer, and suggests that FGFR-targeted therapy might become a promising salvage strategy after lapatinib failure in patients with HER2-positive breast cancer.",
author = "Koichi Azuma and Junji Tsurutani and Kazuko Sakai and Hiroyasu Kaneda and Yasuhito Fujisaka and Masayuki Takeda and Masahiro Watatani and Tokuzo Arao and Taroh Satoh and Isamu Okamoto and Takayasu Kurata and Kazuto Nishio and Kazuhiko Nakagawa",
year = "2011",
month = "4",
day = "1",
doi = "10.1016/j.bbrc.2011.03.002",
language = "English",
volume = "407",
pages = "219--224",
journal = "Biochemical and Biophysical Research Communications",
issn = "0006-291X",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - Switching addictions between HER2 and FGFR2 in HER2-positive breast tumor cells

T2 - FGFR2 as a potential target for salvage after lapatinib failure

AU - Azuma, Koichi

AU - Tsurutani, Junji

AU - Sakai, Kazuko

AU - Kaneda, Hiroyasu

AU - Fujisaka, Yasuhito

AU - Takeda, Masayuki

AU - Watatani, Masahiro

AU - Arao, Tokuzo

AU - Satoh, Taroh

AU - Okamoto, Isamu

AU - Kurata, Takayasu

AU - Nishio, Kazuto

AU - Nakagawa, Kazuhiko

PY - 2011/4/1

Y1 - 2011/4/1

N2 - Agents that target HER2 have improved the prognosis of patients with HER2-amplified breast cancers. However, patients who initially respond to such targeted therapy eventually develop resistance to the treatment. We have established a line of lapatinib-resistant breast cancer cells (UACC812/LR) by chronic exposure of HER2-amplified and lapatinib-sensitive UACC812 cells to the drug. The mechanism by which UACC812/LR acquired resistance to lapatinib was explored using comprehensive gene hybridization. The FGFR2 gene in UACC812/LR was highly amplified, accompanied by overexpression of FGFR2 and reduced expression of HER2, and a cell proliferation assay showed that the IC50 of PD173074, a small-molecule inhibitor of FGFR tyrosine kinase, was 10,000 times lower in UACC812/LR than in the parent cells. PD173074 decreased the phosphorylation of FGFR2 and substantially induced apoptosis in UACC812/LR, but not in the parent cells. FGFR2 appeared to be a pivotal molecule for the survival of UACC812/LR as they became independent of the HER2 pathway, suggesting that a switch of addiction from the HER2 to the FGFR2 pathway enabled cancer cells to become resistant to HER2-targeted therapy. The present study is the first to implicate FGFR in the development of resistance to lapatinib in cancer, and suggests that FGFR-targeted therapy might become a promising salvage strategy after lapatinib failure in patients with HER2-positive breast cancer.

AB - Agents that target HER2 have improved the prognosis of patients with HER2-amplified breast cancers. However, patients who initially respond to such targeted therapy eventually develop resistance to the treatment. We have established a line of lapatinib-resistant breast cancer cells (UACC812/LR) by chronic exposure of HER2-amplified and lapatinib-sensitive UACC812 cells to the drug. The mechanism by which UACC812/LR acquired resistance to lapatinib was explored using comprehensive gene hybridization. The FGFR2 gene in UACC812/LR was highly amplified, accompanied by overexpression of FGFR2 and reduced expression of HER2, and a cell proliferation assay showed that the IC50 of PD173074, a small-molecule inhibitor of FGFR tyrosine kinase, was 10,000 times lower in UACC812/LR than in the parent cells. PD173074 decreased the phosphorylation of FGFR2 and substantially induced apoptosis in UACC812/LR, but not in the parent cells. FGFR2 appeared to be a pivotal molecule for the survival of UACC812/LR as they became independent of the HER2 pathway, suggesting that a switch of addiction from the HER2 to the FGFR2 pathway enabled cancer cells to become resistant to HER2-targeted therapy. The present study is the first to implicate FGFR in the development of resistance to lapatinib in cancer, and suggests that FGFR-targeted therapy might become a promising salvage strategy after lapatinib failure in patients with HER2-positive breast cancer.

UR - http://www.scopus.com/inward/record.url?scp=79953162369&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79953162369&partnerID=8YFLogxK

U2 - 10.1016/j.bbrc.2011.03.002

DO - 10.1016/j.bbrc.2011.03.002

M3 - Article

C2 - 21377448

AN - SCOPUS:79953162369

VL - 407

SP - 219

EP - 224

JO - Biochemical and Biophysical Research Communications

JF - Biochemical and Biophysical Research Communications

SN - 0006-291X

IS - 1

ER -